DexCom (DXCM) Faces Investor Criticism After Disappointing Earnings Report – Hagens Berman

San Francisco, California–(Newsfile Corp. – September 6, 2024) – Hagens Berman calls DexCom, Inc. (NASDAQ:DXCM) investors who have suffered significant losses to report their losses now. The company also encourages anyone with knowledge that can assist in the investigation to contact its attorneys.

Class period: January 8, 2024 – July 25, 2024
Deadline for lead plaintiff: October 21, 2024
Visit: www.hbsslaw.com/investor-fraud/DXCM
Contact the company now: [email protected]
844-916-0895

DexCom, Inc. (DXCM) Securities Class Action Lawsuit:

DexCom, a leading provider of continuous glucose monitoring systems, is under intense scrutiny from investors and analysts following a dismal earnings report. The company’s stock price fell 40% in a single trading session after it reported disappointing second-quarter growth.

Sales in the quarter fell short of analysts’ expectations, prompting management to lower its full-year revenue forecast. That correction prompted analysts to significantly lower their 2025 sales estimates, casting doubt on the company’s future prospects.

The negative sentiment surrounding DexCom was further fueled by influential financial figures. Jim Cramer, host of CNBC’s “Mad Money,” advised viewers to stay away from the company, citing its “really bad mistake” and lack of a clear explanation for its poor results.

Securities analysts have also expressed concerns. On Aug. 5, Baird analyst Jeff Johnson downgraded DexCom from “Outperform” to “Neutral” and lowered his price target, highlighting the company’s recent struggles.

Adding to the company’s troubles, DexCom now faces a securities class action lawsuit. The complaint alleges that the company made misleading statements and failed to disclose potential risks to its earnings prospects.

The lawsuit alleges that management hid several known problems, including a shortage of new patients and slower-than-expected growth in revenue per patient. DexCom management attributed the challenges to disruptive sales force expansion, raising questions about the company’s transparency about its strategic challenges.

Hagens Berman, a leading shareholder rights firm, has launched an investigation into potential violations of U.S. securities laws by DexCom.

According to Reed Kathrein, the Hagens Berman partner leading the investigation, “Our focus is on whether DexCom could have realized how changes in its sales force would disrupt its competitive position and financial results.”

If you invested in DexCom and suffered significant losses or have knowledge that could assist the company’s investigation, report your losses now »

For more information and answers to frequently asked questions about the DexCom case and our investigation, read more »

Whistleblowers: Those with nonpublic information about DexCom should consider their options for assisting in the investigation or take advantage of the SEC Whistleblower Program. Under the new program, whistleblowers who provide original information can receive rewards of up to 30 percent of any successful SEC recovery. For more information, call Reed Kathrein at 844-916-0895 or write to [email protected].

# # #

About Hagens Berman
Hagens Berman is a global, complex plaintiffs’ rights litigation firm with a focus on corporate liability. The firm maintains a robust practice representing investors, as well as whistleblowers, employees, consumers and others in matters that achieve real results for those harmed by corporate negligence and other wrongdoing. The Hagens Berman team has recovered more than $2.9 billion in this area of law. For more information about the firm and its successes, visit hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/222411